BioCentury | Aug 15, 2016
Clinical News

SynCon MERS DNA vaccine: Completed Phase I enrollment

...evaluating a 3-injection regimen of 0.67, 2 and 6 mg DNA per intramuscular dose of GLS-5300...
...KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon MERS DNA vaccine ( INO-4500 , GLS-5300...
BioCentury | Feb 22, 2016
Clinical News

SynCon MERS DNA vaccine: Phase I started

...evaluate a 3-injection regimen of 0.67, 2 and 6 mg DNA per intramuscular dose of GLS-5300...
...KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon MERS DNA vaccine ( INO-4500 , GLS-5300...
BioCentury | Sep 7, 2015
Clinical News

GeneOne, Inovio preclinical data

...In non-human primates, INO-4500 induced 100% protection from a live MERS-CoV challenge. Data were published in...
...Data were published in Science Translational Medicine. In July, Inovio partnered with GeneOne to co-develop INO-4500...
...Science Inc. (KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon MERS DNA vaccine ( INO-4500...
BioCentury | Jul 20, 2015
Company News

Inovio, GeneOne deal

...The companies will co-develop Inovio’s INO-4500 vaccine against Middle East respiratory syndrome (MERS). The Phase I...
...the trial, the partners will seek an additional partner to support further development and commercialization. INO-4500...
Items per page:
1 - 4 of 4